Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Country's Decision or any other Communication
(DEC)
last updated: 25 Jun 2026
No
Commercial Release of the Vectormune FP-LT-AE Vaccine - Technical Opinion No. 2958/2011.
EN
16 Jun 2011
No
- Decision on LMOs for intentional introduction into the environment (according to Article 10 or domestic regulatory framework)
- Decision on LMOs for direct use as food or feed, or for processing (Article 11, LMOs-FFP)
No
Yes
-
Organization:Ceva Saúde Animal Ltda (CEVA)Private sector (business and industry)Rua Manuel Joaquim Filho, 303 Pulínia - SPPaulínia, São Paulo
13140-000, BrazilPhone: 551938337700,Fax: 55193833-7722,Email: alexisgoux@ceva.com,Website: http://www.ceva.com.br/,
Yes
Yes
Yes
- LMOs for processing
No
Approval of the import and/or use of the LMO(s) without conditions
-
BCH-LMO-SCBD-105176-3 Living Modified Organism VECTORMUNE® FP-LT + AE VaccineCeva Saúde Animal Ltda(CEVA) | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-RA-BR-299526-1 Risk Assessment generated by a regulatory process Risk assessment of the Vectormune FP-LT-AE Vaccine - Technical Opinion No. 2958/2011.VECTORMUNE® FP-LT + AE Vaccine | FOWPV, Production of medical or pharmaceutical compounds (human or animal)
- Commercial release 2958-2011.pdf [ Portuguese ]